Cargando…

Isoform-specific NF1 mRNA levels correlate with disease severity in Neurofibromatosis type 1

BACKGROUND: Neurofibromatosis type 1 (NF1) is characterized by an extreme clinical variability both within and between families that cannot be explained solely by the nature of the pathogenic NF1 gene mutations. A proposed model hypothesizes that variation in the levels of protein isoforms generated...

Descripción completa

Detalles Bibliográficos
Autores principales: Assunto, Antonia, Ferrara, Ursula, De Luca, Alessandro, Pivonello, Claudia, Lombardo, Lisa, Piscitelli, Annapina, Tortora, Cristina, Pinna, Valentina, Daniele, Paola, Pivonello, Rosario, Russo, Maria Giovanna, Limongelli, Giuseppe, Colao, Annamaria, Tartaglia, Marco, Strisciuglio, Pietro, Melis, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858644/
https://www.ncbi.nlm.nih.gov/pubmed/31730495
http://dx.doi.org/10.1186/s13023-019-1223-1
Descripción
Sumario:BACKGROUND: Neurofibromatosis type 1 (NF1) is characterized by an extreme clinical variability both within and between families that cannot be explained solely by the nature of the pathogenic NF1 gene mutations. A proposed model hypothesizes that variation in the levels of protein isoforms generated via alternative transcript processing acts as modifier and contributes to phenotypic variability. RESULTS: Here we used real-time quantitative PCR to investigate the levels of two major NF1 mRNA isoforms encoding proteins differing in their ability to control RAS signaling (isoforms I and II) in the peripheral blood leukocytes of 138 clinically well-characterized NF1 patients and 138 aged-matched healthy controls. As expected, expression analysis showed that NF1 isoforms I and II levels were significantly lower in patients than controls. Notably, these differences were more evident when patients were stratified according to the severity of phenotype. Moreover, a correlation was identified when comparing the levels of isoform I mRNA and the severity of NF1 features, with statistically significant lower levels associated with a severe phenotype (i.e., occurrence of learning disability/intellectual disability, optic gliomas and/or other neoplasias, and/or cerebrovascular disease) as well as in patients with cognitive impairment. CONCLUSIONS: The present findings provide preliminary evidence for a role of circuits controlling NF1 transcript processing in modulating NF1 expressivity, and document an association between the levels of neurofibromin isoform I mRNA and the severity of phenotype and cognitive impairment in NF1.